Medical device alert
On 22 February 2013, the Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) issued a draft guidance titled, Distinguishing Medical Device Recalls from Product Enhancements and Associated Reporting Requirements - Draft Guidance for Industry and Food and Drug Administration Staff, which describes how to differentiate violative devices from non-violative devices with respect to Corrections and Removals (21 C.F.R. Part 806), as well as Voluntary Recalls (21 C.F.R. Part 7). The purpose of the guidance is to clarify when a change to a device constitutes a medical device recall, to distinguish those instances from product enhancements that do not meet the definition of a medical device recall, and to identify the associated regulatory reporting requirements for each type of activity.
The guidance does not address when changes to marketed devices trigger new product submissions. In addition, the guidance does not address issues regarding radiological health devices concerning radiation defects or failures to comply with radiation safety performance standards described in 21 C.F.R. Parts 1020-1050…
If you are registered and logged in to the site, click on the link below to read the rest of the Hogan Lovells briefing. If not, please register or sign in with your details below.
News from Hogan Lovells
News from The Lawyer
Briefings from Hogan Lovells
Judgments handed down from the People’s Court all over the country will be available online from 1 January 2014, as part of the initiative by the Supreme People’s Court of China (SPC) to increase judicial transparency.
An issue that comes up fairly regularly in redundancy selection is whether employers must consider all employees in similar roles or whether they can opt for a ‘pool of one’.
Analysis from The Lawyer
The Lawyer’s latest Top 50 litigation firms list shows that business for dispute specialists is roaring along while new in-depth detail reveals the winning strategies
The Russian legal market faces a new era as the government opens the door to greater business transparency, but not everything is open to scrutiny